Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
Retrieved on:
Thursday, May 11, 2023
Teva Pharmaceuticals, Patent, Metal, Human, Gian Maria Annovi, PD, Alzheimer's disease, Environmental Toxicology and Pharmacology, United States Patent and Trademark Office, Clinical trial, Toxicology, ATM, Down syndrome, International Conference on Afghanistan, London (2006), Patient, Procházka, Process chemistry, Mouse, Research, AD, FDA, News, NYSE, Conference, Chemical process, Pharmaceutical industry, EU, Pharmacology
BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent accomplishments.
Key Points:
- BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent accomplishments.
- At a recent R&D webcast on April 20, 2023, the Company:
Reviewed its ongoing clinical programs in AD and PD. - Explained the results from the pre-planned blinded interim analysis of the ongoing Phase 3 study for early PD, announced on March 31, 2023.
- Financial Results (for the quarter ending March 31, 2023)
Cash and cash equivalents were $16.8 million.